Omnicell, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. Unaudited results; comparisons are with the corresponding 2021 periods. Omnicell provides medication-management technology, products, software, and services to healthcare systems and pharmacies.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | $348.1 million | $296.4 million | $998.3 million | $821.0 million |
| Gross profit / margin | $159.1 million / 45.7% | $146.8 million / 49.5% | $467.2 million / 46.8% | $405.4 million / 49.4% |
| Operating income | $18.5 million | $29.4 million | $36.0 million | $77.9 million |
| Net income | $16.8 million | $29.3 million | $34.1 million | $63.9 million |
| Diluted EPS | $0.37 | $0.61 | $0.73 | $1.35 |
Q3 revenue increased 17% year over year; product revenue rose 15% and services and other revenue rose 23%. Nine-month revenue increased 22%. Growth reflected demand for automated dispensing systems and other products, expanded services, and contributions from acquisitions. SaaS, subscription software, and technology-enabled services revenue was $47.6 million in Q3, up from $28.9 million.
Margins and earnings weakened despite revenue growth. Management attributed lower gross margin to inflationary inventory costs, higher employee and travel expenses, service-business investment, lower 340B revenue, and service-revenue mix. Operating expenses rose 20% in Q3 and 32% year to date, including higher staffing, acquisition-related amortization, and other operating costs. Lower convertible-note imputed interest expense following adoption of new accounting guidance partly offset these pressures.
Cash flow, balance sheet, and debt
- Operating cash flow: Used $4.4 million in the first nine months of 2022, versus $172.2 million provided in 2021. The 2022 result included a $116.9 million increase in receivables and a $32.3 million increase in inventory, among other working-capital uses.
- Investing and financing: Investing activities used $41.4 million, principally for capital expenditures and software development. Financing activities used $24.5 million, including $52.2 million of share repurchases, partly offset by employee stock-plan proceeds.
- Cash and liquidity: Cash and cash equivalents were $266.4 million at September 30, down from $349.1 million at year-end 2021. Working capital was $472.5 million, and the current ratio was 2.3:1. Management said available cash, expected operating cash flows, and credit availability should cover anticipated needs for at least 12 months.
- Debt: Convertible senior notes had $575.0 million principal and a $565.8 million net carrying value; they mature in September 2025 and bear a 0.25% coupon. The $500 million revolving credit facility had no borrowings outstanding. The company reported compliance with credit-agreement covenants.
- Other balance-sheet items: Accounts receivable and unbilled receivables were $354.1 million, inventories $147.1 million, and deferred revenue $148.4 million at September 30, 2022.
Material changes and notable items
- Net income fell 43% in Q3 and 47% for the first nine months, while revenue grew. Gross margin declined by approximately 3.8 percentage points in Q3 and 2.6 points year to date.
- The May 2022 ransomware incident delayed invoicing, collections, and customer implementations. Omnicell said substantially all critical systems were restored, delayed processes had returned to normal by quarter-end, and most delayed implementations were completed or expected in Q4. It reported $13.5 million of incident expenses through September, partially offset by $11.1 million of expected insurance recoveries.
- Omnicell acquired Hub and Spoke Innovations in January 2022 for approximately $3.4 million. Results also included full-period contributions from 2021 acquisitions FDS Amplicare, ReCept, and MarkeTouch Media, affecting comparability.
- The company recorded $5.3 million of restructuring expense in the first nine months and $5.4 million of lease-asset impairment and abandonment charges associated with facility optimization.
- Cash used for stock repurchases was $52.2 million in the first nine months; no repurchases occurred in Q3. The remaining authorization under the 2016 program was $2.7 million.
Outlook, risks, and contingencies
The filing does not provide a clear numerical revenue or earnings forecast for the full year. Management described continued investment in its Autonomous Pharmacy strategy and expects demand opportunities across point-of-care, central pharmacy, specialty pharmacy and 340B, and retail markets. It noted that customer purchasing and installation timing, supply availability, staffing, and implementation capacity affect revenue conversion.
- Risks highlighted include inflation, labor shortages, supply-chain disruption, customer delays in capital-equipment purchases or installations, foreign-exchange movements, and uncertainty around COVID-19 impacts.
- Reduced provider use of 340B services following drug-manufacturer actions has weighed on related revenue; litigation and possible regulatory or legislative changes could further affect the business.
- Cybersecurity, privacy, and healthcare-data regulation remain material risks. The ransomware event resulted in required breach notification to fewer than 350 individuals.
- A class action alleging violations of Illinois biometric privacy law was subject to a settlement process, with mediation scheduled for November 2022. The company recorded no material accrual, stating a material loss was reasonably possible but not probable and that any possible range was not reasonably estimable or not deemed material.
- Non-cancelable purchase commitments totaled $186.9 million, including $115.9 million expected to be paid during the remainder of 2022.
Most important facts for investors to verify
- Whether revenue growth converts into improved gross margin, operating income, and positive operating cash flow.
- Receivables, inventory, collections, and installation timing, including completion of delayed customer implementations.
- Actual ransomware-related costs and insurance recoveries, and whether cybersecurity or privacy issues generate further liabilities.
- Trends in 340B services and the potential effects of manufacturer actions, litigation, or regulatory changes.
- Debt conversion conditions, 2025 maturity obligations, and continued compliance with credit-facility covenants.
- The outcome and potential cost of the Illinois biometric privacy litigation.